Logo

American Heart Association

  57
  0


Final ID:

Do Emerging HFpEF Treatments Work? The Role of Non-disease Modifying Treatments including SGLT2i, MRAs, GLP1s, and implantable hemodynamic monitors in Cardiac Amyloidosis.

  • Cuddy, Sarah  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Griffin, Jan  ( Medical University of South Carolina , Charleston , South Carolina , United States )
  • Author Disclosures:
    Sarah Cuddy: DO have relevant financial relationships ; Consultant:bridgebio:Active (exists now) ; Consultant:attralus:Active (exists now) ; Research Funding (PI or named investigator):NIH:Active (exists now) ; Research Funding (PI or named investigator):aha:Active (exists now) ; Consultant:intellia:Past (completed) ; Research Funding (PI or named investigator):intellia:Active (exists now) ; Research Funding (PI or named investigator):alnylam:Active (exists now) ; Research Funding (PI or named investigator):alexion:Active (exists now) ; Research Funding (PI or named investigator):astrazenca:Active (exists now) ; Speaker:pfizer:Past (completed) ; Advisor:pfizer:Past (completed) ; Advisor:novo nordisk:Active (exists now) ; Advisor:astrazeneca:Active (exists now) ; Speaker:bridgebio:Past (completed) ; Speaker:novo nordisk:Past (completed) | Jan Griffin: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

More abstracts on this topic:
More abstracts from these authors:
Novel Therapies in the Management of Cardiac Amyloidosis and Access to Care

Falk Rodney, Kittleson Michelle, Cuddy Sarah

Discussant: nex-z, also known as NTLA-2001

Griffin Jan, Davis Margot, Cuddy Sarah

You have to be authorized to contact abstract author. Please, Login
Not Available